

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT	DISEASE Small intestine GIST	PHYSICIAN	ORDERING PHYSICIAN Yeh, Yi-Chen	SPECIMEN	SPECIMEN SITE Small Intestine
	NAME Lin, Ke-Wei		MEDICAL FACILITY Taipei Veterans General Hospital		SPECIMEN ID S110-61752 G (PF21074)
	DATE OF BIRTH 08 August 1994		ADDITIONAL RECIPIENT None		SPECIMEN TYPE Slide Deck
	SEX Male		MEDICAL FACILITY ID 205872		DATE OF COLLECTION 26 May 2021
	MEDICAL RECORD # 31733194		PATHOLOGIST Not Provided		SPECIMEN RECEIVED 24 December 2021

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - 0 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

KIT Y503_F504insAY

1 Disease relevant genes with no reportable alterations: PDGFRA

† See About the Test in appendix for details.

Report Highlights

- Variants with diagnostic implications that may indicate a specific cancer type: **KIT Y503_F504insAY** (p. 3)
- Targeted therapies with NCCN categories of evidence in this tumor type: **Imatinib** (p. 4), **Regorafenib** (p. 4), **Ripretinib** (p. 5), **Sunitinib** (p. 5), **Avapritinib** (p. 4), **Nilotinib** (p. 6), **Sorafenib** (p. 7)
- Evidence-matched clinical trial options based on this patient's genomic findings: (p. 8)

BIOMARKER FINDINGS

Microsatellite status - MS-Stable

Tumor Mutational Burden - 0 Muts/Mb

GENOMIC FINDINGS

KIT - Y503_F504insAY

10 Trials see p. 8

THERAPY AND CLINICAL TRIAL IMPLICATIONS

No therapies or clinical trials. see Biomarker Findings section

No therapies or clinical trials. see Biomarker Findings section

THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)		THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)	
Imatinib	1	Nilotinib	2A
Regorafenib	1	Sorafenib	2A
Ripretinib	1	Dasatinib	
Sunitinib	1	Ponatinib	
Avapritinib	2A		

 NCCN category

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 11 January 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1267623-01

BIOMARKER FINDINGS

BIOMARKER

Microsatellite status

RESULT

MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors¹⁻³, including approved therapies nivolumab and pembrolizumab⁴. In a retrospective

analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, $p=0.001$)⁵.

FREQUENCY & PROGNOSIS

MSI is generally rare in GIST⁶, although conflicting data have been published⁷. The prognostic significance of MSI in GIST has not been an active area of investigation (PubMed, Feb 2021).

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of

genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor⁸. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2⁸⁻¹⁰. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers¹¹⁻¹³. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins^{8,10,12-13}.

BIOMARKER

Tumor Mutational Burden

RESULT

0 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1¹⁴⁻¹⁶, anti-PD-1 therapies¹⁴⁻¹⁷, and combination nivolumab and ipilimumab¹⁸⁻²³. In multiple pan-tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors^{14-17,24}. Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors¹⁴.

Analyses across several solid tumor types reported that patients with higher TMB (defined as ≥ 16 -20 Muts/Mb) achieved greater clinical benefit from PD-1 or PD-L1-targeting monotherapy, compared with patients with higher TMB treated with chemotherapy²⁵ or those with lower TMB treated with PD-1 or PD-L1-targeting agents¹⁵. However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB ≥ 10 Muts/Mb (based on this assay or others) compared to those with TMB < 10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials^{17,24}. Together, these studies suggest that patients with TMB ≥ 10 Muts/Mb may derive clinical benefit from PD-1 or PD-L1 inhibitors.

FREQUENCY & PROGNOSIS

Gastrointestinal stromal tumors (GIST) harbor a median TMB of 2.5 mutations per megabase (mut/Mb), and 0% of cases have high TMB (> 20 muts/Mb)²⁶. Published data investigating the

prognostic implications of TMB in GIST are limited (PubMed, Sep 2021).

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma²⁷⁻²⁸ and cigarette smoke in lung cancer²⁹⁻³⁰, treatment with temozolomide-based chemotherapy in glioma³¹⁻³², mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes³³⁻³⁷, and microsatellite instability (MSI)^{33,36-37}. This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD-1- or PD-L1-targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types^{15-16,24}.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 11 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1267623-01

GENOMIC FINDINGS
GENE
KIT
ALTERATION

Y503_F504insAY

TRANSCRIPT ID

NM_000222

CODING SEQUENCE EFFECT

1509_1510insGCCTAT

VARIANT ALLELE FREQUENCY (% VAF)

41.0%

POTENTIAL TREATMENT STRATEGIES
— Targeted Therapies —

On the basis of clinical evidence, primarily in GIST, AML, and systemic mastocytosis, KIT activating alterations are associated with sensitivity to KIT tyrosine kinase inhibitors including imatinib, sunitinib, sorafenib, dasatinib, nilotinib, pazopanib, regorafenib, ponatinib, midostaurin, avapritinib, and ripretinib³⁸⁻⁴⁵. The use of mTOR inhibitors as an alternative therapeutic strategy has demonstrated limited success in KIT-mutated, imatinib-resistant melanoma, with 1 PR and 3 SD observed for 4 patients treated with everolimus⁴⁶. However, no responses were observed for 10 patients with mastocytosis following everolimus monotherapy, with 8/10 patients harboring the KIT D816V mutation⁴⁷. The role of KIT amplification as a biomarker for response to mTOR inhibitors has

not been investigated (PubMed, Mar 2021). In a dose escalation study of GIST patients who developed KIT resistant mutations, most commonly in exons 11 and 17 after progressing on imatinib, treatment with the higher dosage of PLX9486 alone and in the lower dosage in combination with pexidartinib reported clinical benefit rates of 64% (7/11) and 67% (6/9), respectively⁴⁸.

— Potential Resistance —

The KIT exon 9 insertion Y503_F504insAY has been associated with reduced sensitivity to ponatinib in one preclinical study⁴⁹.

FREQUENCY & PROGNOSIS

KIT mutation has been reported in 54-72% of GIST cases, and the majority of these mutations affect exon 9 or exon 11⁵⁰⁻⁵². It is estimated that up to 95% of GISTs overexpress the KIT protein, and KIT mutation has been reported to be an early event in the development of GIST^{50,53}. Mutations in exon 11 of KIT are associated with a significantly greater response rate to imatinib, compared to individuals with mutations in exon 9 or without mutations in KIT⁵⁴⁻⁵⁵. Studies comparing patients with GIST treated with imatinib to those treated with placebo indicate that the presence of exon 11 in-frame deletions is associated with a significantly longer recurrence-free survival in univariate analysis; similar results were not observed for patients with exon 11 insertions, exon 11 point mutations, exon 9

mutations, or no KIT mutation⁵⁶. Overall, patients with exon 11 mutations experienced a benefit from adjuvant imatinib therapy, which is in agreement with several previous studies⁵⁴⁻⁵⁷, but although the reported effect on overall survival is favorable, it does not always reach statistical significance⁵⁶⁻⁵⁷. However, patients that develop imatinib resistance have a poorer prognosis than those without including a reduced 5 year survival rate⁵⁸.

FINDING SUMMARY

KIT (also called c-KIT) encodes a cell surface tyrosine kinase receptor that, upon ligand binding and dimerization, activates the PI3K-AKT and RAS-MAPK signaling pathways⁵⁹. KIT aberrations, including point mutations, translocations, amplification, and overexpression, have been associated with various malignancies, and KIT is considered an oncoprotein⁶⁰. KIT exon 9 insertions Y503_F504insAY (also described as A502_Y503dup) and A502_Y503insSA (S501_A502dup) have been reported to be activating and associated with response to imatinib, sunitinib, or masitinib in GIST and mast cell leukemia⁶¹⁻⁶⁷.

POTENTIAL DIAGNOSTIC IMPLICATIONS

KIT mutations are characteristic drivers of GIST and may aid in guiding targeted therapy approaches in this setting (NCCN GIST Guidelines, v1.2021)⁶⁸.

ORDERED TEST # ORD-1267623-01

THERAPIES WITH CLINICAL BENEFIT

IN PATIENT'S TUMOR TYPE

Avapritinib

Assay findings association

KIT

Y503_F504insAY

AREAS OF THERAPEUTIC USE

Avapritinib is a selective kinase inhibitor of PDGFRA and KIT activating mutations. It is FDA approved for the treatment of unresectable or metastatic gastrointestinal stromal tumor (GIST) that is positive for PDGFRA mutation in exon 18, including the resistance mutation D842V. It is also approved to treat advanced systemic mastocytosis. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of prospective Phase 1 and Phase 2 studies in KIT-mutated GIST^{38,69} and systemic mastocytosis (SM)⁷⁰⁻⁷¹, as well as a case report in metastatic vulvar melanoma⁷², KIT mutation may predict sensitivity to avapritinib.

SUPPORTING DATA

Avapritinib has primarily been studied in the context of PDGFRA- and KIT-mutated GIST⁷³⁻⁷⁴ and KIT-mutated mastocytosis⁷⁵⁻⁷⁷. For previously treated patients with GIST and PDGFRA exon 18 mutations, avapritinib treatment was associated with an ORR of 86% (37/43; 3 CRs, 34 PRs) and a clinical benefit rate (CBR) of 95% in the Phase 1 NAVIGATOR trial⁷⁴. A similar cohort treated in the ≥4th-line setting with no approved treatment options achieved an ORR of 22% (24/111; 1 CR, 23 PRs) and duration of response of 10.2 months from avapritinib in this trial; patients with PDGFRA exon 18 mutations other than D842V experienced an ORR of 17%⁷⁴.

Imatinib

Assay findings association

KIT

Y503_F504insAY

AREAS OF THERAPEUTIC USE

Imatinib targets the BCR-ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT-positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/ myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical and preclinical data in KIT-mutated⁷⁸⁻⁸¹, KIT-amplified^{78,81-83}, or KIT-expressing tumors⁸⁴⁻⁹¹, KIT activating alterations may confer

sensitivity to imatinib.

SUPPORTING DATA

Clinical studies in GIST have reported that imatinib treatment results in significantly longer recurrence-free survival (RFS) and OS^{57,84}. A meta-analysis of imatinib clinical trials suggests that patients with GIST harboring KIT exon 11 mutations respond better to imatinib than those without⁹². Several Phase 3 trials of imatinib, including a 10-year outcomes study, reported significantly increased OS in patients with GIST harboring KIT exon 11 mutations relative to those with KIT exon 9 mutations⁹³⁻⁹⁴. A case study has reported a PR and 5-year disease stabilization upon treatment with imatinib in a patient with GIST harboring a PDGFRA exon 12 mutation⁹⁵.

Regorafenib

Assay findings association

KIT

Y503_F504insAY

AREAS OF THERAPEUTIC USE

Regorafenib is a small-molecule inhibitor of multiple kinases, including RET, VEGFRs, PDGFRs, KIT, and RAF family proteins. It is FDA approved to treat hepatocellular carcinoma that has been previously treated with sorafenib, metastatic colorectal cancer (CRC), or advanced gastrointestinal stromal tumors (GISTs). Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical evidence in gastrointestinal stromal tumor, activating KIT alterations may confer sensitivity to regorafenib⁹⁶. Preclinical and limited clinical data indicate that secondary imatinib-resistant mutations, including V654A and A-loop alterations at residues D816, D820, N822, and A829, remain sensitive to regorafenib^{49,97}.

SUPPORTING DATA

A Phase 2 follow-up study of regorafenib treatment for patients with advanced GIST and a KIT exon 11 mutation reported a longer median PFS (13.4 months) compared to patients with KIT/PDGFR wild-type, non-SDH-deficient tumors (1.6 months)⁹⁸. Regorafenib is approved in the third line for advanced gastrointestinal stromal tumors (GISTs) based on a Phase 3 randomized study comparing regorafenib to placebo; patients who had progressed on imatinib and sunitinib demonstrated significantly longer median PFS when treated with regorafenib (4.8 vs. 0.9 months)⁴¹. A Phase 2 study of regorafenib in the second-line setting for patients with imatinib-resistant advanced GIST reported a median PFS of 36.3 weeks⁹⁹.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 11 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1267623-01

THERAPIES WITH CLINICAL BENEFIT

IN PATIENT'S TUMOR TYPE

Ripretinib

Assay findings association
KIT

Y503_F504insAY

AREAS OF THERAPEUTIC USE

Ripretinib is a selective kinase inhibitor of PDGFRA and KIT. It is FDA approved for the treatment of patients with gastrointestinal stromal tumor (GIST). Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical evidence in KIT-mutated GIST¹⁰⁰ as well as strong preclinical evidence¹⁰¹, KIT mutation may predict sensitivity to ripretinib.

SUPPORTING DATA

The Phase 3 INVICTUS study comparing ripretinib with placebo for patients with previously treated advanced gastrointestinal stromal tumor (GIST) reported improved median PFS (6.3 vs. 1.0 months, HR=0.15), median OS (15.1 vs. 6.6 months, HR=0.36), and ORR (9.4% vs. 0%)¹⁰². A Phase 1 study evaluating ripretinib in previously treated GIST also reported ORRs of 24%, 24%, or 9% as second-line, third-line or fourth-or-later-line therapies, respectively¹⁰⁰.

Sunitinib

Assay findings association
KIT

Y503_F504insAY

AREAS OF THERAPEUTIC USE

Sunitinib is a small-molecule tyrosine kinase inhibitor that targets PDGFRs, VEGFRs, KIT, FLT3, CSF-1R, and RET. It is FDA approved for the treatment of advanced or metastatic pancreatic neuroendocrine tumors, gastrointestinal stromal tumors (GISTs) in patients who have progressed on or are intolerant to imatinib, and advanced renal cell carcinoma (RCC) as well as for the adjuvant treatment of patients at high risk of recurrent RCC after nephrectomy. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical and preclinical data in KIT-mutated¹⁰³⁻¹⁰⁸ or KIT-expressing tumors^{103,109}, KIT activating alterations may predict sensitivity to sunitinib.

SUPPORTING DATA

The median time to progression in patients with imatinib-refractory or -intolerant GIST treated with sunitinib was 27.3 weeks, as compared with 6.4 weeks for patients treated with placebo¹¹⁰. Patients with imatinib-resistant GIST harboring KIT exon 11 mutations exhibited worse progression-free survival (12.3 months) and clinical benefit rate (34%) than patients with exon 9 mutations (26.9 months; 58%) or wild type KIT (30.5 months; 56%) during treatment with sunitinib in a Phase 1/2 trial¹⁰⁴. However, these data were from pooled exon 11 mutations, and the presence of secondary mutations may have impaired the response of these patients; KIT V560D was potentially inhibited by sunitinib in vitro in the absence of secondary mutations¹⁰⁴.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 11 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1267623-01

THERAPIES WITH CLINICAL BENEFIT

IN OTHER TUMOR TYPE

Dasatinib

Assay findings association

KIT

Y503_F504insAY

AREAS OF THERAPEUTIC USE

Dasatinib is a kinase inhibitor that targets the BCR-ABL fusion protein, SRC family kinase receptors, KIT, EPHA2, and PDGFR-beta. It is FDA approved for the treatment of certain subtypes of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL). Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical evidence in melanoma¹¹¹⁻¹¹² and preclinical evidence in other cancer types¹¹³⁻¹¹⁴, activating KIT alterations may confer sensitivity to dasatinib. Preclinical and limited clinical data indicate that secondary imatinib-resistant mutations, including V654A and A-loop alterations at residues D816, D820, N822, and

A829, remain sensitive to dasatinib¹¹⁴⁻¹¹⁹.

SUPPORTING DATA

A Phase 2 trial of dasatinib treatment in patients with kinase inhibitor-naïve gastrointestinal stromal tumors (GIST) reported an overall response rate of 67% (29/43), with 13 complete responses and 16 partial responses¹²⁰. A Phase 2 trial of dasatinib in patients with GIST who were refractory to imatinib and sunitinib reported a partial response rate of 32% (15/47), with 21% (10/47) of patients demonstrating progression-free survival for greater than six months¹²¹. Preclinical studies of a mouse model of GIST showed that combined treatment with imatinib and dasatinib resulted in the arrest of tumor cell growth and an increase in cell death, and also a decrease in KIT and AKT phosphorylation¹²².

Nilotinib

Assay findings association

KIT

Y503_F504insAY

AREAS OF THERAPEUTIC USE

Nilotinib targets tyrosine kinases such as ABL (including BCR-ABL), PDGFRs, KIT, CSF1R, DDR1, and DDR2. It is FDA approved to treat newly diagnosed pediatric or adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with Ph+ CML in chronic or accelerated phase with resistance or intolerance to prior therapy including imatinib, and pediatric patients with Ph+ CML in chronic phase with resistance or intolerance to prior tyrosine-kinase inhibitor therapy. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical and preclinical data in KIT-mutated¹²³⁻¹²⁷, KIT-amplified¹²³, or KIT-expressing tumors¹²⁸, KIT activating alterations may confer sensitivity to nilotinib.

SUPPORTING DATA

A Phase 3 trial of nilotinib in 240 patients with advanced gastrointestinal stromal tumors (GIST) who had failed prior imatinib and sunitinib treatment showed no significant difference in progression-free survival between nilotinib and best supportive care, but overall survival was increased in nilotinib-treated patients¹²⁹. A Phase 2 study has shown that nilotinib as a single agent third-line therapy (after imatinib and sunitinib treatment) for GIST had an objective response rate of 3% (1/35) and stable disease at six-weeks in 66% (23/35) of patients¹³⁰. A Phase 2 study of nilotinib in patients with GIST resistant to both imatinib and sunitinib reported responses in 10% (5/52) of patients¹³¹. A Phase 2 clinical trial showed that nilotinib was well tolerated and suggested that it may be particularly useful in treating a subset of GIST with KIT exon 17 mutations¹³².

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 11 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1267623-01

THERAPIES WITH CLINICAL BENEFIT

IN OTHER TUMOR TYPE

Ponatinib

Assay findings association

KIT

Y503_F504insAY

AREAS OF THERAPEUTIC USE

Ponatinib is a multikinase inhibitor targeting BCR-ABL, RET, KIT, FLT-3, PDGFRs, VEGFRs, FGFRs, and other tyrosine kinases. It is FDA approved for the treatment of advanced, T315I-mutated chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), as well as for CML and Ph+ ALL patients for whom no other tyrosine kinase inhibitor is indicated. Please see the drug label for full prescribing information.

GENE ASSOCIATION

KIT exon 9 and 11 activating mutations have demonstrated sensitivity to ponatinib in several preclinical cell models¹³³⁻¹³⁸, with clinical efficacy demonstrated in patients with GIST exhibiting exon 11 mutations^{49,139} and imatinib resistance¹⁴⁰. KIT Y503_F504insAY has been shown to result in decreased sensitivity to ponatinib in a preclinical study⁴⁹.

SUPPORTING DATA

Data from a Phase 2 trial in GIST indicated that ponatinib induced a clinical benefit rate (CBR; patients exhibiting complete response, partial response, or stable disease for at least 16 weeks) in 55% of patients with KIT exon 11 mutations compared with a CBR of 27% in patients lacking mutations in exon 11¹⁴⁰. Ponatinib has also demonstrated robust preclinical activity in patient-derived gastrointestinal stromal tumor (GIST) cell lines against multiple imatinib-resistant KIT mutations, including the gatekeeper residue, T670I, and secondary mutations within the activation loop, including those at residues D816, D820, N822, and A829⁴⁹. Moreover, ponatinib displayed clinical activity in 2 out of 3 patients with refractory GIST, all of whom had been previously treated with, at a minimum, imatinib, sunitinib, and regorafenib⁴⁹.

Sorafenib

Assay findings association

KIT

Y503_F504insAY

AREAS OF THERAPEUTIC USE

Sorafenib is a kinase inhibitor that targets the RAF kinases, KIT, FLT3, RET, VEGFRs, and PDGFRs. It is FDA approved for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and recurrent or metastatic differentiated thyroid carcinoma. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical and preclinical data in KIT-mutated^{119,141-147} or KIT-expressing tumors¹⁴⁸⁻¹⁵¹, KIT activating alterations may predict sensitivity to sorafenib.

SUPPORTING DATA

Phase 2 studies of sorafenib in patients with gastrointestinal stromal tumors (GIST) previously treated with imatinib and sunitinib have reported partial responses in 10-13% of patients and stable disease in 52-57% of patients^{145,152}. A retrospective analysis of sorafenib in 124 patients with GIST previously treated with imatinib and sunitinib reported that 57% (70/124) of patients achieved disease stabilization and 10% (12/124) achieved partial response¹⁵³.

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 11 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1267623-01

CLINICAL TRIALS

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and

should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require

medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or visit <https://www.foundationmedicine.com/genomic-testing#support-services>.

GENE
KIT
ALTERATION
 Y503_F504insAY

RATIONALE
 KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K-AKT-mTOR

pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation. KIT Y503_F504insAY has been associated with decreased sensitivity to ponatinib.

NCT04337463
PHASE NULL

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

TARGETS
 mTORC1, mTORC2, PD-1

LOCATIONS: Chongqing (China), Chengdu (China)

NCT04803318
PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
 mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK

LOCATIONS: Guangzhou (China)

NCT02461849
PHASE 2

Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy

TARGETS
 KIT, ABL

LOCATIONS: Seoul (Korea, Republic of)

NCT03609424
PHASE 1/2

PDR001 Plus Imatinib for Metastatic or Unresectable GIST

TARGETS
 KIT, ABL, PD-1

LOCATIONS: Seoul (Korea, Republic of)

NCT03564691
PHASE 1

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

TARGETS
 ITL4, FGFRs, RET, PDGFRA, VEGFRs, KIT, PD-1

LOCATIONS: Seoul (Korea, Republic of), Tokyo (Japan), Haifa (Israel), Petah Tikva (Israel), Ramat Gan (Israel), Tel Aviv (Israel), Warszawa (Poland), Gdansk (Poland), Heraklion (Greece), Washington

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 11 January 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1267623-01

CLINICAL TRIALS

NCT04409223
PHASE 3

Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib

TARGETS
VEGFR2, VEGFR3, PDGFRB, FLT3, KIT,
PDGFRA, FLT1, VEGFR1, VEGFRs,
CSF1R, RET

LOCATIONS: Beijing (China)

NCT04633122
PHASE 2

A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib

TARGETS
FLT3, VEGFRs, CSF1R, KIT, RET,
PDGFRA

LOCATIONS: Beijing (China)

NCT04008797
PHASE 1

A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor

TARGETS
CBP, Beta-catenin, FGFRs, RET,
PDGFRA, VEGFRs, KIT

LOCATIONS: Osakasayama (Japan), Chuo-Ku (Japan), Kashiwa (Japan)

NCT02413736
PHASE 3

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

TARGETS
KIT, ABL

LOCATIONS: Helsinki (Finland)

NCT02260505
PHASE 3

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)

TARGETS
KIT, ABL

LOCATIONS: Vandoeuvre-les-Nancy (France), Lille (France), Reims (France), Besançon (France), Paris (France), Villejuif (France), Lyon (France), Saint-priest-en-jarez (France), Marseille (France), Rennes (France)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

 Electronically signed by Erik Williams, M.D. | 11 January 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | 1.888.988.3639

 Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1267623-01

APPENDIX
Variants of Unknown Significance

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

CD22
D50N

CSF1R
T621M

DDR1
D644Y

FGFR3
V505I

IDH2
M397V

MERTK
P802H

NOTCH3
E739K

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 11 January 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1267623-01

APPENDIX
Genes Assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	ACVR1B	AKT1	AKT2	AKT3	ALK	ALOX12B	AMER1 (FAM123B)	APC
AR	ARAF	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX	AURKA
AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2	BCL6
BCOR	BCORL1	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2
BTK	C11orf30 (EMSY)	C17orf39 (GID4)	CALR	CARD11	CASP8	CBFB	CBL	CCND1
CCND2	CCND3	CCNE1	CD22	CD274 (PD-L1)	CD70	CD79A	CD79B	CDC73
CDH1	CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B	CDKN2A	CDKN2B
CDKN2C	CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL	CSF1R	CSF3R
CTCF	CTNNA1	CTNNB1	CUL3	CUL4A	CXCR4	CYP17A1	DAXX	DDR1
DDR2	DIS3	DNMT3A	DOT1L	EED	EGFR	EP300	EPHA3	EPHB1
EPHB4	ERBB2	ERBB3	ERBB4	ERCC4	ERG	ERRF1	ESR1	EZH2
FAM46C	FANCA	FANCC	FANCG	FANCL	FAS	FBXW7	FGF10	FGF12
FGF14	FGF19	FGF23	FGF3	FGF4	FGF6	FGFR1	FGFR2	FGFR3
FGFR4	FH	FLCN	FLT1	FLT3	FOXL2	FUBP1	GABRA6	GATA3
GATA4	GATA6	GNA11	GNA13	GNAQ	GNAS	GRM3	GSK3B	H3F3A
HDAC1	HGF	HNF1A	HRAS	HSD3B1	ID3	IDH1	IDH2	IGF1R
IKBKE	IKZF1	INPP4B	IRF2	IRF4	IRS2	JAK1	JAK2	JAK3
JUN	KDMSA	KDM5C	KDM6A	KDR	KEAP1	KEL	KIT	KLHL6
KMT2A (MLL)	KMT2D (MLL2)	KRAS	LTK	LYN	MAF	MAP2K1 (MEK1)	MAP2K2 (MEK2)	MAP2K4
MAP3K1	MAP3K13	MAPK1	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1
MERTK	MET	MITF	MKKN1	MLH1	MPL	MRE11A	MSH2	MSH3
MSH6	MST1R	MTAP	MTOR	MUTYH	MYC	MYCL (MYCL1)	MYCN	MYD88
NBN	NF1	NF2	NFE2L2	NFKBIA	NKX2-1	NOTCH1	NOTCH2	NOTCH3
NPM1	NRAS	NSD3 (WHSC1L1)	NTSC2	NTRK1	NTRK2	NTRK3	P2RY8	PALB2
PARK2	PARP1	PARP2	PARP3	PAX5	PBRM1	PDCD1 (PD-1)	PDCD1LG2 (PD-L2)	PDGFRA
PDGFRB	PDK1	PIK3C2B	PIK3C2G	PIK3CA	PIK3CB	PIK3R1	PIM1	PMS2
POLD1	POLE	PPARG	PPP2R1A	PPP2R2A	PRDM1	PRKAR1A	PRKCI	PTCH1
PTEN	PTPN11	PTPRO	QKI	RAC1	RAD21	RAD51	RAD51B	RAD51C
RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	REL	RET
RICTOR	RNF43	ROS1	RPTOR	SDHA	SDHB	SDHC	SDHD	SETD2
SF3B1	SGK1	SMAD2	SMAD4	SMARCA4	SMARCB1	SMO	SNCAIP	SOC3
SOX2	SOX9	SPEN	SPOP	SRC	STAG2	STAT3	STK11	SUFU
SYK	TBX3	TEK	TET2	TGFBR2	TIPARP	TNFAIP3	TNFRSF14	TP53
TSC1	TSC2	TYRO3	U2AF1	VEGFA	VHL	WHSC1	WT1	XPO1
XRCC2	ZNF217	ZNF703						

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	BCL2	BCR	BRAF	BRCA1	BRCA2	CD74	EGFR	ETV4
ETV5	ETV6	EWSR1	EZR	FGFR1	FGFR2	FGFR3	KIT	KMT2A (MLL)
MSH2	MYB	MYC	NOTCH2	NTRK1	NTRK2	NUTM1	PDGFRA	RAF1
RARA	RET	ROS1	RSP02	SDC4	SLC34A2	TERC*	TERT**	TPRSS2

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Loss of Heterozygosity (LOH) score

Microsatellite (MS) status

Tumor Mutational Burden (TMB)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 11 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1267623-01

APPENDIX
About FoundationOne®CDx

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium.


ABOUT FOUNDATIONONE CDx

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details:
www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLES

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture-selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g., gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification - equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss - equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials
Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fractional-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 11 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1267623-01

APPENDIX

About FoundationOne®CDx

- Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.
- TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
 - The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
 - Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
 - Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine

whether the patient is a candidate for biopsy.

- Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in <https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/> report the frequency of *HER2* overexpression as 20% in breast cancer. Based on the F1CDx *HER2* CDx concordance study, approximately 10% of *HER2* amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	%CV*
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

*Interquartile Range = 1st Quartile to 3rd Quartile

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *PALB2*, *PMS2*, *POLE*, *RAD51C*, *RAD51D*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *TSC2*, and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1*, *CBL*, *DNMT3A*, *IDH2*, *JAK2*, *KMT2D* (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 11 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 | CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 | CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 | CLIA: 22D2027531

ORDERED TEST # ORD-1267623-01

APPENDIX

About FoundationOne®CDx

cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
mut/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 5.2.0

The median exon coverage for this sample is 907x

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 11 January 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1267623-01

APPENDIX
References

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Campanella NC, et al. Oncol Lett (2017) pmid: 29113157
7. Fukasawa T, et al. Jpn. J. Cancer Res. (2000) pmid: 11123422
8. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
9. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
10. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
11. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
12. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
13. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
14. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
15. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
16. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
17. Cristescu R, et al. Science (2018) pmid: 30309915
18. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
19. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
20. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
21. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
22. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
23. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
24. Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526
25. Legrand et al., 2018; ASCO Abstract 12000
26. Chalmers ZR, et al. Genome Med (2017) pmid: 28420421
27. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
28. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
29. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
30. Rizvi NA, et al. Science (2015) pmid: 25765070
31. Johnson BE, et al. Science (2014) pmid: 24336570
32. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
33. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
34. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
35. Heitzner E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
36. Nature (2012) pmid: 22810696
37. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
38. Evans EK, et al. Sci Transl Med (2017) pmid: 29093181
39. Abbaspour Babaei M, et al. Drug Des Devel Ther (2016) pmid: 27536065
40. Ramaswamy A, et al. J Gastrointest Oncol (2016) pmid: 27563456
41. Demetri GD, et al. Lancet (2013) pmid: 23177515
42. Gotlib J, et al. N. Engl. J. Med. (2016) pmid: 27355533
43. Jawhar M, et al. Blood (2017) pmid: 28424161
44. Xu X, et al. Int J Clin Exp Pathol (2014) pmid: 25031773
45. Gotlib J, et al. Blood (2005) pmid: 15972446
46. Si L, et al. J. Clin. Oncol. (2012) pmid: 22162580
47. Parikh SA, et al. Leuk Lymphoma (2010) pmid: 20038218
48. Wagner et al., 2018; ASCO Abstract 11509
49. Garner AP, et al. Clin. Cancer Res. (2014) pmid: 25239608
50. Mikami T, et al. Hum. Pathol. (2013) pmid: 24119563
51. Wang C, et al. Scand. J. Gastroenterol. (2013) pmid: 23862765
52. Andersson J, et al. Gastroenterology (2006) pmid: 16697720
53. Corless CL, et al. Nat. Rev. Cancer (2011) pmid: 22089421
54. Joensuu H, et al. Lancet (2013) pmid: 23623056
55. Eur. J. Cancer (2013) pmid: 23206668
56. Corless CL, et al. J. Clin. Oncol. (2014) pmid: 24638003
57. Joensuu H, et al. JAMA (2012) pmid: 22453568
58. Peixoto A, et al. J Gastrointest Oncol (2018) pmid: 29755776
59. Int. J. Biochem. Cell Biol. (1999) pmid: 10582339
60. Semin. Oncol. (2004) pmid: 15175998
61. Yuzawa S, et al. Cell (2007) pmid: 17662946
62. Lux ML, et al. Am. J. Pathol. (2000) pmid: 10702394
63. Mital A, et al. Eur. J. Haematol. (2011) pmid: 21362052
64. Corless CL, et al. J. Clin. Oncol. (2004) pmid: 15365079
65. Guo T, et al. Clin. Cancer Res. (2009) pmid: 19861442
66. Georjin-Lavialle S, et al. Eur. J. Haematol. (2012) pmid: 22324351
67. Liu NN, et al. Lab. Invest. (2013) pmid: 23459373
68. Casali PG, et al. Ann Oncol (2018) pmid: 30188977
69. Heinrich et al., 2017; ASCO Abstract 11011
70. DeAngelo DJ, et al. Nat Med (2021) pmid: 34873347
71. Gotlib J, et al. Nat Med (2021) pmid: 34873345
72. Cocorocchio E, et al. Ther Adv Med Oncol (2020) pmid: 32821296
73. Heinrich MC, et al. Lancet Oncol (2020) pmid: 32615108
74. Heinrich et al., 2019; ASCO Abstract 11022
75. Radia et al., 2019; EHA Abstract S830
76. Deninger et al., 2018; EHA Abstract PF612
77. DeAngelo et al., 2017; ASH Abstract 2
78. Carvajal RD, et al. JAMA (2011) pmid: 21642685
79. Debiec-Rychter M, et al. Eur. J. Cancer (2006) pmid: 16624552
80. Heinrich MC, et al. J. Clin. Oncol. (2003) pmid: 14645423
81. Hodi FS, et al. J. Clin. Oncol. (2013) pmid: 23775962
82. Wei X, et al. Oncol. Res. (2019) pmid: 30075827
83. Guo J, et al. J. Clin. Oncol. (2011) pmid: 21690468
84. Dematteo RP, et al. Lancet (2009) pmid: 19303137
85. Faivre S, et al. J. Clin. Oncol. (2005) pmid: 16135502
86. Alcedo JC, et al. Head Neck (2004) pmid: 15350030
87. Brandwein JM, et al. Leukemia (2011) pmid: 21403650
88. Hotte SJ, et al. J. Clin. Oncol. (2005) pmid: 15659505
89. Reardon DA, et al. Br. J. Cancer (2009) pmid: 19904263
90. Kamenz T, et al. World J. Gastroenterol. (2006) pmid: 16570351
91. Wang YY, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15650049
92. Zhi X, et al. PLoS ONE (2013) pmid: 24223922
93. Demetri et al., 2014; ASCO Abstract 10508
94. Heinrich MC, et al. J. Clin. Oncol. (2008) pmid: 18955451
95. Kocáková I, et al. Klin Onkol (2014) pmid: 24635438
96. Ben-Ami et al., 2016; 27371698; Van Looy et al.
97. Van Looy T, et al. Clin Sarcoma Res (2014) pmid: 25132955
98. Ben-Ami E, et al. Ann. Oncol. (2016) pmid: 27371698
99. Takahashi et al., 2020; ASCO GI abstract 823
100. George et al., 2018; ASCO Abstract 11511
101. Smith BD, et al. Cancer Cell (2019) pmid: 31085175
102. Blay JY, et al. Lancet Oncol. (2020) pmid: 32511981
103. Minor DR, et al. Clin. Cancer Res. (2012) pmid: 22261812
104. Heinrich MC, et al. J. Clin. Oncol. (2008) pmid: 18955458
105. Buchbinder EI, et al. Cancer (2015) pmid: 26264378
106. Reichardt P, et al. BMC Cancer (2016) pmid: 26772734
107. Hirai F, et al. Mol Clin Oncol (2016) pmid: 27073655
108. Goemans BF, et al. Leuk. Res. (2010) pmid: 20435347
109. Mahipal A, et al. Melanoma Res. (2012) pmid: 23114504
110. Goodman VL, et al. Clin. Cancer Res. (2007) pmid: 17332278
111. Kalinsky et al., 2016; ASCO 2016 Abstract 9501
112. Kluger HM, et al. Cancer (2011) pmid: 21523734
113. Mpakou VE, et al. Leuk. Res. (2013) pmid: 23149070
114. Wasag B, et al. Exp. Hematol. (2011) pmid: 21689725
115. Todd JR, et al. Pigment Cell Melanoma Res (2013) pmid: 23582185
116. Zhao J, et al. Cancer Sci. (2014) pmid: 24205792
117. Schittenhelm MM, et al. Cancer Res. (2006) pmid: 16397263
118. Ustun C, et al. Leuk. Res. (2009) pmid: 18986703
119. Guo T, et al. Clin. Cancer Res. (2007) pmid: 17699867
120. Montemurro et al., 2012; ASCO Abstract 10033
121. Trent et al., 2011; ASCO Abstract 10006
122. Rossi F, et al. Mol. Cancer Res. (2010) pmid: 20736294
123. Lee SJ, et al. Oncologist (2015) pmid: 26424760
124. Carvajal RD, et al. Clin. Cancer Res. (2015) pmid: 25695690
125. Hochhaus A, et al. J. Cancer Res. Clin. Oncol. (2015) pmid: 26002753
126. Blay JY, et al. Lancet Oncol. (2015) pmid: 25882987
127. Kajimoto N, et al. Int J Clin Exp Pathol (2015) pmid: 26722383
128. Sako H, et al. PLoS ONE (2014) pmid: 25221952
129. Reichardt P, et al. Ann. Oncol. (2012) pmid: 22357255
130. Sawaki A, et al. Cancer (2011) pmid: 21456006
131. Montemurro M, et al. Eur. J. Cancer (2009) pmid: 19467857
132. Cauchi C, et al. Cancer Chemother. Pharmacol. (2012) pmid: 22119758
133. Schrock et al., 2013; ASCO Abstract B266
134. Garner et al., 2013; AACR Abstract 3394
135. Lierman E, et al. Leukemia (2012) pmid: 22301675
136. Jin B, et al. Mol. Cancer Ther. (2014) pmid: 24552773
137. Gleixner KV, et al. Haematologica (2013) pmid: 23539538
138. Gozgit JM, et al. Mol. Cancer Ther. (2011) pmid: 21482694
139. Heinrich et al., 2014; ASCO Abstract 1050
140. Heinrich et al., 2014; ASCO Abstract 10506
141. Quintás-Cardama A, et al. Nat Clin Pract Oncol (2008) pmid: 18936790
142. Bisagni G, et al. J Thorac Oncol (2009) pmid: 19461405
143. Handolias D, et al. Br. J. Cancer (2010) pmid: 20372153
144. Dişel U, et al. Lung Cancer (2011) pmid: 20970876
145. Park SH, et al. Invest New Drugs (2012) pmid: 22270258
146. Catania C, et al. Onco Targets Ther (2014) pmid: 24855380
147. Hu S, et al. Mol. Cancer Ther. (2008) pmid: 18483300
148. Llovet JM, et al. Clin. Cancer Res. (2012) pmid: 22374331
149. Zhang HL, et al. Clin Genitourin Cancer (2013) pmid: 23058498
150. Seino S, et al. Gastroenterology (2014) pmid: 25450081
151. Li XF, et al. Med. Oncol. (2009) pmid: 18846437
152. Campbell et al., 2011; ASCO Gastrointestinal Cancers Symposium

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 11 January 2022
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1267623-01

APPENDIX

References

153. Montemurro M, et al. Eur. J. Cancer (2013) PMID: 23140824

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 11 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531